Abstract
In the present work we developed and optimized moxifloxacin loaded PLGA nanodispersions for enhanced ocular delivery of moxifloxacin. The optimized nanodispersions were prepared by double emulsification solvent evaporation method using high pressure homogenizer (500 bar pressure, 2 cycles) to homogenize primary emulsion. Particle size of nanodispersion was found to be dependent on PLGA concentration, PLGA:drug ratio, PVA concentration and W:O phase volume ratio whereas drug encapsulation was related to PLGA concentration and PLGA:drug ratio. Encapsulation efficiency of optimized nanodispersion was 62.5% with a mean particle size of around 118.5 nm which makes them a suitable candidate for ocular administration. Drug release kinetic studies indicate a sustained release profile of moxifloxacin from nanodispersions. In addition, in vitro and in vivo studies have revealed that PLGA nanodispersions were non irritant, prevent ocular drainage of moxifloxacin with enhanced ocular bioavailability by 3-fold.